DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
cAMPS-Sp triethylammonium salt (HB0566)
Description:Potent, specific cAMP-dependent protein kinases activator. Cell-permeable.
Purity:>98%
-
CAT335 (HB8146)
Description:K2P2.1 (TREK-1) modulator. Selectively and irreversibly activates TREK-1CG* but not wild-type K2P2.1 (TREK-1)
Purity:>98%
-
-
Clozapine N-oxide (CNO) (freebase) (HB1807)
Description:Prototypical DREADD activator. Clozapine metabolite.
Purity:>98%
- Description:
Dihydrochloride salt of CNO - the prototypical DREADD activator
Purity:>98%
-
-
-
1-EBIO (HB1045)
Description:Epithelial KCa channel activator. Promotes ESC differentiation into cardiomyocytes.
Purity:>98%
-
EC 23 (HB2592)
Description:Synthetic retinoid. Induces neural differentiation of hESCs.
Purity:>99%
